2018
Homologous recombination deficiency and host anti-tumor immunity in triple-negative breast cancer
Telli ML, Stover DG, Loi S, Aparicio S, Carey LA, Domchek SM, Newman L, Sledge GW, Winer EP. Homologous recombination deficiency and host anti-tumor immunity in triple-negative breast cancer. Breast Cancer Research And Treatment 2018, 171: 21-31. PMID: 29736741, DOI: 10.1007/s10549-018-4807-x.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntineoplastic AgentsB7-H1 AntigenBiomarkers, TumorDisease SusceptibilityDNA DamageDNA RepairFemaleGene Expression Regulation, NeoplasticGenes, BRCA1Genes, BRCA2Germ-Line MutationHomologous RecombinationHumansImmunityImmunomodulationMolecular Targeted TherapyProgrammed Cell Death 1 ReceptorTriple Negative Breast NeoplasmsConceptsHost anti-tumor immunityAnti-tumor immunityHomologous recombination deficiencyBreast cancerPurposeTriple-negative breast cancerAnti-tumor immune cellsRecombination deficiencyTriple-negative breast cancerCare systemic therapyImmune-directed therapiesImmune cell subsetsHomologous recombination DNA repair deficiencyBRCA2 mutation carriersBiomarker-driven approachBreast cancer subtypesPARP inhibitor olaparibHR-deficient tumorsDNA repair capacityMetastatic diseaseSystemic therapyImmune infiltratesImproved prognosisCell subsetsImmune cellsWorse outcomes
2016
Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer
Telli ML, Timms KM, Reid J, Hennessy B, Mills GB, Jensen KC, Szallasi Z, Barry WT, Winer EP, Tung NM, Isakoff SJ, Ryan PD, Greene-Colozzi A, Gutin A, Sangale Z, Iliev D, Neff C, Abkevich V, Jones JT, Lanchbury JS, Hartman AR, Garber JE, Ford JM, Silver DP, Richardson AL. Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer. Clinical Cancer Research 2016, 22: 3764-3773. PMID: 26957554, PMCID: PMC6773427, DOI: 10.1158/1078-0432.ccr-15-2477.Peer-Reviewed Original ResearchFrequency of Germline Mutations in 25 Cancer Susceptibility Genes in a Sequential Series of Patients With Breast Cancer
Tung N, Lin NU, Kidd J, Allen BA, Singh N, Wenstrup RJ, Hartman AR, Winer EP, Garber JE. Frequency of Germline Mutations in 25 Cancer Susceptibility Genes in a Sequential Series of Patients With Breast Cancer. Journal Of Clinical Oncology 2016, 34: 1460-1468. PMID: 26976419, PMCID: PMC4872307, DOI: 10.1200/jco.2015.65.0747.Peer-Reviewed Original ResearchMeSH KeywordsAdultAge FactorsAgedAged, 80 and overBreast NeoplasmsFemaleGene Expression ProfilingGene Expression Regulation, NeoplasticGenes, BRCA1Genes, BRCA2Genetic Predisposition to DiseaseGenetic TestingGerm-Line MutationHigh-Throughput Nucleotide SequencingHumansJewsMiddle AgedNeoplasm StagingOvarian NeoplasmsPredictive Value of TestsPrevalenceProspective StudiesRetrospective StudiesRisk FactorsTriple Negative Breast NeoplasmsConceptsCancer predisposition genesTriple-negative breast cancerBreast cancer predisposition genesBreast cancerPredisposition genesGermline mutationsOvarian cancerNext-generation sequencingBRCA1/2 mutationsCancer susceptibility genesSingle cancer centerFamily cancer historyBreast/ovarian cancerOvarian cancer predisposition genesPredictors of mutationsSusceptibility genesSelect patientsSequential patientsAshkenazi Jewish ancestryCancer CenterCancer historyClinical managementFamily historyBreast/ovarian cancer susceptibility geneOvarian cancer susceptibility genes
2015
Tailoring adjuvant chemotherapy regimens for patients with triple negative breast cancer
Stover DG, Winer EP. Tailoring adjuvant chemotherapy regimens for patients with triple negative breast cancer. The Breast 2015, 24: s132-s135. PMID: 26255198, DOI: 10.1016/j.breast.2015.07.032.Peer-Reviewed Original ResearchConceptsTriple-negative breast cancerBreast cancerAdjuvant chemotherapyHigh-risk triple negative breast cancerLong-term outcome dataAnthracycline-taxane combinationsBRCA mutation carriersStandard of careNegative breast cancerPoor prognosis subtypeAdjuvant settingStandard regimensToxic regimensMetastatic settingCytotoxic chemotherapySystemic therapyImmune infiltratesTumor characteristicsMutation carriersOutcome dataWarrants further considerationStage ISpecific subgroupsChemotherapyCancerLocal Therapy Decision-Making and Contralateral Prophylactic Mastectomy in Young Women with Early-Stage Breast Cancer
Rosenberg SM, Sepucha K, Ruddy KJ, Tamimi RM, Gelber S, Meyer ME, Schapira L, Come SE, Borges VF, Golshan M, Winer EP, Partridge AH. Local Therapy Decision-Making and Contralateral Prophylactic Mastectomy in Young Women with Early-Stage Breast Cancer. Annals Of Surgical Oncology 2015, 22: 3809-3815. PMID: 25930247, PMCID: PMC4598267, DOI: 10.1245/s10434-015-4572-6.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAnxietyBody Mass IndexBreast NeoplasmsDecision MakingDirective CounselingFearFemaleGenes, BRCA1Genes, BRCA2Genetic TestingHumansLymphatic MetastasisMastectomy, SegmentalMutationNeoplasm StagingParityPatient ParticipationProphylactic Surgical ProceduresReceptor, ErbB-2RecurrenceTumor BurdenYoung AdultConceptsBreast-conserving surgeryContralateral prophylactic mastectomyEarly-stage breast cancerUnilateral mastectomyBreast cancerYoung womenProphylactic mastectomyUnilateral stage ILarger tumor sizeOngoing cohort studyGood psychosocial supportResultsMedian ageClinical characteristicsCohort studyHER2 positivityNodal involvementLocal therapyLower BMITumor sizeBRCA mutationsPatient-driven decisionSurgical decisionMethodsAs partMultinomial logistic regressionStage I
2013
Perceptions, knowledge, and satisfaction with contralateral prophylactic mastectomy among young women with breast cancer: a cross-sectional survey.
Rosenberg SM, Tracy MS, Meyer ME, Sepucha K, Gelber S, Hirshfield-Bartek J, Troyan S, Morrow M, Schapira L, Come SE, Winer EP, Partridge AH. Perceptions, knowledge, and satisfaction with contralateral prophylactic mastectomy among young women with breast cancer: a cross-sectional survey. Annals Of Internal Medicine 2013, 159: 373-81. PMID: 24042365, PMCID: PMC3968260, DOI: 10.7326/0003-4819-159-6-201309170-00003.Peer-Reviewed Original ResearchConceptsContralateral prophylactic mastectomyContralateral breast cancerBreast cancerCross-sectional surveyYoung womenProphylactic mastectomyBilateral breast cancerBreast cancer worryAge 40 yearsCommunity medical centerBRCA2 mutation carriersSusan G. KomenBilateral mastectomyUnaffected breastCancer worryMedical CenterMutation carriersMost womenCancerEvidence-based decisionsMastectomyRecall biasWomenRiskActual risk
2010
Triple-negative breast cancer: disease entity or title of convenience?
Carey L, Winer E, Viale G, Cameron D, Gianni L. Triple-negative breast cancer: disease entity or title of convenience? Nature Reviews Clinical Oncology 2010, 7: 683-692. PMID: 20877296, DOI: 10.1038/nrclinonc.2010.154.Peer-Reviewed Original ResearchMeSH KeywordsAntineoplastic AgentsBRCA1 ProteinBreast NeoplasmsCarcinoma, Ductal, BreastCase ManagementCombined Modality TherapyDrug Resistance, NeoplasmFemaleGene Expression ProfilingGene Expression Regulation, NeoplasticGenes, BRCA1Genes, erbB-2HumansMitotic IndexNeoplasm InvasivenessNeoplasm MetastasisNeoplasm ProteinsNeoplasm Recurrence, LocalPrognosisReceptor, ErbB-2Receptors, EstrogenReceptors, ProgesteroneConceptsTriple negative breast cancer tumorsNew systemic therapiesGood initial responseGroup of tumorsPoly (ADP-ribose) polymerase (PARP) inhibitorsBreast cancer tumorsHormonal therapySystemic therapyLuminal subtypeWorse prognosisClinical trialsDisease entityMTOR inhibitorsAngiogenesis inhibitorsPolymerase inhibitorsTherapeutic agentsCancer tumorsInitial responseTherapyTumorsInhibitorsSrc kinaseAgentsChemotherapyPatientsEfficacy of Neoadjuvant Cisplatin in Triple-Negative Breast Cancer
Silver DP, Richardson AL, Eklund AC, Wang ZC, Szallasi Z, Li Q, Juul N, Leong CO, Calogrias D, Buraimoh A, Fatima A, Gelman RS, Ryan PD, Tung NM, De Nicolo A, Ganesan S, Miron A, Colin C, Sgroi DC, Ellisen LW, Winer EP, Garber JE. Efficacy of Neoadjuvant Cisplatin in Triple-Negative Breast Cancer. Journal Of Clinical Oncology 2010, 28: 1145-1153. PMID: 20100965, PMCID: PMC2834466, DOI: 10.1200/jco.2009.22.4725.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntineoplastic AgentsBreast NeoplasmsCisplatinDNA MethylationDNA-Binding ProteinsFemaleGenes, BRCA1Genes, p53HumansMiddle AgedMutationNeoadjuvant TherapyNuclear ProteinsOligonucleotide Array Sequence AnalysisPromoter Regions, GeneticReceptor, ErbB-2Receptors, EstrogenReceptors, ProgesteroneTumor Protein p73Tumor Suppressor ProteinsConceptsTriple-negative breast cancerBreast cancerSubset of TNBCCisplatin responseSporadic triple-negative breast cancerGood pathologic responsePathologic treatment responseSingle-agent cisplatinCycles of cisplatinStandard adjuvant chemotherapyPathologic complete responseSubset of patientsPredictors of responseBasal-like tumorsPretreatment tumor samplesBreast cancer treatmentHER2/neuBRCA1 promoter methylationBRCA1 mRNA expressionAdjuvant chemotherapyNeoadjuvant cisplatinNeoadjuvant trialsDefinitive surgeryGene expression signaturesPartial response
2008
Triple-Negative Breast Cancer: Risk Factors to Potential Targets
Schneider BP, Winer EP, Foulkes WD, Garber J, Perou CM, Richardson A, Sledge GW, Carey LA. Triple-Negative Breast Cancer: Risk Factors to Potential Targets. Clinical Cancer Research 2008, 14: 8010-8018. PMID: 19088017, DOI: 10.1158/1078-0432.ccr-08-1208.Peer-Reviewed Original ResearchMeSH KeywordsBreast NeoplasmsFemaleGenes, BRCA1HumansReceptor, ErbB-2Receptors, EstrogenReceptors, ProgesteroneRisk FactorsConceptsTriple-negative breast cancerBreast cancerRisk factorsTherapeutic approachesBasal-like breast cancerConventional cytotoxic therapyBasal-like subtypeNovel therapeutic targetClinical research programCytotoxic therapyClinical behaviorConventional agentsTherapeutic targetDistinct subtypesCancerImportant subgroupSubtypesPotential targetUnique subgroupClinical samplesMolecular biology platformsSubgroupsMolecular biologyDistinct outcomesFocus article
2002
Pre-Counseling Education Materials for BRCA Testing: Does Tailoring Make a Difference?
Skinner CS, Schildkraut JM, Berry D, Calingaert B, Marcom PK, Sugarman J, Winer EP, Iglehart JD, Futreal PA, Rimer BK. Pre-Counseling Education Materials for BRCA Testing: Does Tailoring Make a Difference? Genetic Testing And Molecular Biomarkers 2002, 6: 93-105. PMID: 12215248, DOI: 10.1089/10906570260199348.Peer-Reviewed Original ResearchConceptsGenetic testingOvarian cancer susceptibilityTumor RegistryMean ageOvarian cancer gene BRCA1Ovarian cancerFamily historyMutation carriersBRCA testingBaseline surveyCancer susceptibilityEstimation of riskBehavioral targetsPrint materialsGreater improvementBreastFollowup surveyEducation materialsWomenGenes BRCA1Decision aidRiskBRCA1
2000
Testing for Hereditary Breast and Ovarian Cancer in the Southeastern United States
Miron A, Schildkraut J, Rimer B, Winer E, Skinner C, Futreal P, Culler D, Calingaert B, Clark S, Marcom P, Iglehart J. Testing for Hereditary Breast and Ovarian Cancer in the Southeastern United States. Annals Of Surgery 2000, 231: 624-634. PMID: 10767783, PMCID: PMC1421049, DOI: 10.1097/00000658-200005000-00002.Peer-Reviewed Original ResearchConceptsProphylactic surgeryPreventive surgeryOvarian cancerFree genetic testingProspective clinical trialsBreast cancer patientsHereditary breast cancerPositive test resultsUncertain clinical significanceMore heterogeneous populationsBaseline characteristicsCancer patientsBaseline questionnaireClinical trialsTime of entryBreast cancerClinical significanceHeterogeneous syndromeSurgeryHereditary breastNumber of womenDeleterious gene mutationsBRCA2 genesGenetic testingSpecial populations
1999
Attitudes, knowledge, and risk perceptions of women with breast and/or ovarian cancer considering testing for BRCA1 and BRCA2.
Bluman L, Rimer B, Berry D, Borstelmann N, Iglehart J, Regan K, Schildkraut J, Winer E. Attitudes, knowledge, and risk perceptions of women with breast and/or ovarian cancer considering testing for BRCA1 and BRCA2. Journal Of Clinical Oncology 1999, 17: 1040-6. PMID: 10071299, DOI: 10.1200/jco.1999.17.3.1040.Peer-Reviewed Original ResearchConceptsOvarian cancerBRCA2 mutationsHigh-risk womenPercent of womenBaseline questionnairePhysician referralCancer riskChallenges cliniciansGenetic testingKnowledge deficitsWomenCancerGene mutationsBreastBRCA2PatientsBaseline knowledgeRiskBRCA1Cancer geneticsTrialsRisk perceptionHigher proportionMutationsPerception of risk
1998
Testing for the BRCA1 and BRCA2 Breast-Ovarian Cancer Susceptibility Genes
Tengs TO, Winer EP, Paddock S, Aguilar-Chavez O, Berry DA. Testing for the BRCA1 and BRCA2 Breast-Ovarian Cancer Susceptibility Genes. Medical Decision Making 1998, 18: 365-375. PMID: 10372578, DOI: 10.1177/0272989x9801800402.Peer-Reviewed Original ResearchAdultAgedBreast NeoplasmsDecision Support TechniquesFemaleGenes, BRCA1Genes, Tumor SuppressorGenetic Predisposition to DiseaseGenetic TestingHumansIncidenceMarkov ChainsMastectomyMiddle AgedOvarian NeoplasmsOvariectomyPredictive Value of TestsQuality-Adjusted Life YearsRisk AssessmentSurvival AnalysisUnited StatesOverestimation of Hereditary Breast Cancer Risk
Iglehart J, Miron A, Rimer B, Winer E, Berry D, Shildkraut J. Overestimation of Hereditary Breast Cancer Risk. Annals Of Surgery 1998, 228: 375-384. PMID: 9742920, PMCID: PMC1191495, DOI: 10.1097/00000658-199809000-00010.Peer-Reviewed Original ResearchConceptsOvarian cancerHereditary factorsBRCA2 mutationsHereditary breast cancer riskIntensive clinical servicesTest-negative womenExpert panelBreast cancer riskCarrier probabilitiesAffected womenFamily historyCancer riskHereditary riskCancerClinical servicesBreastWomenHigher risk perceptionPretest educationWomen's perceptionsPersonal historyRiskBRCA1Disease-associated mutationsBRCA2Sequence analysis of BRCA1 and BRCA2: correlation of mutations with family history and ovarian cancer risk.
Frank TS, Manley SA, Olopade OI, Cummings S, Garber JE, Bernhardt B, Antman K, Russo D, Wood ME, Mullineau L, Isaacs C, Peshkin B, Buys S, Venne V, Rowley PT, Loader S, Offit K, Robson M, Hampel H, Brener D, Winer EP, Clark S, Weber B, Strong LC, Thomas A. Sequence analysis of BRCA1 and BRCA2: correlation of mutations with family history and ovarian cancer risk. Journal Of Clinical Oncology 1998, 16: 2417-25. PMID: 9667259, DOI: 10.1200/jco.1998.16.7.2417.Peer-Reviewed Original ResearchInformed Consent for BRCA1 and BRCA2 Testing
Rimer B, Sugarman J, Winer E, Bluman L, Lerman C. Informed Consent for BRCA1 and BRCA2 Testing. Breast Disease 1998, 10: 99-114. PMID: 15687553, DOI: 10.3233/bd-1998-101-212.Peer-Reviewed Original Research
1997
Genetic Testing for Susceptibility to Breast Cancer: Findings from Women's Focus Groups
Tessaro I, Borstelmann N, Regan K, Rimer B, Winer E. Genetic Testing for Susceptibility to Breast Cancer: Findings from Women's Focus Groups. Journal Of Women's Health 1997, 6: 317-327. PMID: 9201666, DOI: 10.1089/jwh.1997.6.317.Peer-Reviewed Original ResearchConceptsBreast cancerGenetic testingLoss of insuranceSupport needsPositive test resultsWomen's focus groupsFocus groupsUnaffected womenLifestyle changesMore public educationWomen's knowledgeMedical treatmentBRCA1 testingBRCA1 mutationsCancerWomenLifestyle choicesEffect of testingBalanced informationWomen's decisionsPhysiciansFamily membersFocus group discussionsSuch testingWomen's concernsA Review of Hereditary Breast Cancer: From Screening to Risk Factor Modification
Warmuth M, Sutton L, Winer E. A Review of Hereditary Breast Cancer: From Screening to Risk Factor Modification. The American Journal Of Medicine 1997, 102: 407-415. PMID: 9217624, DOI: 10.1016/s0002-9343(97)00093-4.Peer-Reviewed Original ResearchConceptsRisk factor modificationBreast cancerFactor modificationGenetic testingBreast cancer riskBreast cancer casesHereditary breast cancerPotential prophylactic measuresClinical managementBRCA2 mutationsCancer casesCancer riskProphylactic measuresWay patientsCancerGene mutationsGenetic mutationsGenetic testsGenetic aspectsMajor advancesBRCA1MutationsScreeningPatientsDisease